Literature DB >> 17005662

Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.

Ke-Qin Xin1, Hiroaki Mizukami, Masashi Urabe, Yoshihiko Toda, Kaori Shinoda, Atsushi Yoshida, Kenji Oomura, Yoshitsugu Kojima, Motohide Ichino, Dennis Klinman, Keiya Ozawa, Kenji Okuda.   

Abstract

The ability of adeno-associated virus serotype 1 to 8 (AAV1 to AAV8) vectors expressing the human immunodeficiency virus type 1 (HIV-1) Env gp160 (AAV-HIV) to induce an immune response was evaluated in BALB/c mice. The AAV5 vector showed a higher tropism for both mouse and human dendritic cells (DCs) than did the AAV2 vector, whereas other AAV serotype vectors transduced DCs only poorly. AAV1, AAV5, AAV7, and AAV8 were more highly expressed in muscle cells than AAV2. An immunogenicity study of AAV serotypes indicates that AAV1, AAV5, AAV7, and AAV8 vectors expressing the Env gp160 gene induced higher HIV-specific humoral and cell-mediated immune responses than the AAV2 vector did, with the AAV5 vector producing the best responses. Furthermore, mice injected with DCs that had been transduced ex vivo with an AAV5 vector expressing the gp160 gene elicited higher HIV-specific cell-mediated immune responses than did DCs transduced with AAV1 and AAV2 vectors. We also found that AAV vectors produced by HEK293 cells and insect cells elicit similar levels of antigen-specific immune responses. These results demonstrate that the immunogenicity of AAV vectors depends on their tropism for both antigen-presenting cells (such as DCs) and non-antigen-presenting cells (such as muscular cells) and that AAV5 is a better vector than other AAV serotypes. These results may aid in the development of AAV-based vaccine and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005662      PMCID: PMC1676308          DOI: 10.1128/JVI.00890-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor.

Authors:  Jamal Meghrous; Marc G Aucoin; Danielle Jacob; Parminder S Chahal; Normand Arcand; Amine A Kamen
Journal:  Biotechnol Prog       Date:  2005 Jan-Feb

2.  In vivo inhibition of hippocampal Ca2+/calmodulin-dependent protein kinase II by RNA interference.

Authors:  A M Babcock; D Standing; K Bullshields; E Schwartz; C M Paden; D J Poulsen
Journal:  Mol Ther       Date:  2005-06       Impact factor: 11.454

3.  Use of adeno-associated viral vector for delivery of small interfering RNA.

Authors:  Raghuvir S Tomar; Hittu Matta; Preet M Chaudhary
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

4.  Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells.

Authors:  Maurizio Chiriva-Internati; Yong Liu; Emanuela Salati; Weiping Zhou; Zhiqing Wang; Fabio Grizzi; Juan J Roman; Seah H Lim; Paul L Hermonat
Journal:  Eur J Immunol       Date:  2002-01       Impact factor: 5.532

5.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.

Authors:  W A Aldrich; C Ren; A F White; S-Z Zhou; S Kumar; C B Jenkins; D R Shaw; T V Strong; P L Triozzi; S Ponnazhagan
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

7.  Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3.

Authors:  S Muramatsu; H Mizukami; N S Young; K E Brown
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

8.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors.

Authors:  Michael D Moore; Michael J McGarvey; Rebecca A Russell; Bryan R Cullen; Myra O McClure
Journal:  J Gene Med       Date:  2005-07       Impact factor: 4.565

10.  Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery.

Authors:  Weidong Zhang; Rajeswari Singam; Gary Hellermann; Xiaoyuan Kong; Homero San Juan; Richard F Lockey; Shuen-Ju Wu; Kevin Porter; Shyam S Mohapatra
Journal:  Genet Vaccines Ther       Date:  2004-08-09
View more
  38 in total

1.  Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells.

Authors:  Leila N Laredj; Peter Beard
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.

Authors:  Zhujun Ao; Xiaoxia Wang; Alexander Bello; Kallesh Danappa Jayappa; Zhe Yu; Keith Fowke; Xinying He; Xi Chen; Junhua Li; Gary Kobinger; Xiaojian Yao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

3.  Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy.

Authors:  Matthieu Perreau; Franck Mennechet; Nicolas Serratrice; Joel N Glasgow; David T Curiel; Harald Wodrich; Eric J Kremer
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

Authors:  Cathryn S Mah; Darin J Falk; Sean A Germain; Jeffry S Kelley; Melissa A Lewis; Denise A Cloutier; Lara R DeRuisseau; Thomas J Conlon; Kerry O Cresawn; Thomas J Fraites; Martha Campbell-Thompson; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2010-01-26       Impact factor: 11.454

Review 5.  Strategies to modulate immune responses: a new frontier for gene therapy.

Authors:  Valder R Arruda; Patricia Favaro; Jonathan D Finn
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

6.  Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery.

Authors:  Dan Xu; Christopher M Walker
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

7.  Cross-Presentation of Skin-Targeted Recombinant Adeno-associated Virus 2/1 Transgene Induces Potent Resident Memory CD8+ T Cell Responses.

Authors:  David-Alexandre Gross; Alexandre Ghenassia; Laurent Bartolo; Dominique Urbain; Sofia Benkhelifa-Ziyyat; Stéphanie Lorain; Jean Davoust; Pascal Chappert
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

8.  Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity.

Authors:  Yuanyuan Xiao; Manish Muhuri; Shaoyong Li; Wanru Qin; Guangchao Xu; Li Luo; Jia Li; Alexander J Letizia; Sean K Wang; Ying Kai Chan; Chunmei Wang; Sebastian P Fuchs; Dan Wang; Qin Su; M Abu Nahid; George M Church; Michael Farzan; Li Yang; Yuquan Wei; Ronald C Desrosiers; Christian Mueller; Phillip Wl Tai; Guangping Gao
Journal:  JCI Insight       Date:  2019-05-21

9.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1.

Authors:  Appakkudal R Anand; Anil Prasad; Ritu R Bradley; Yadwinder S Deol; Tirumuru Nagaraja; Xianghui Ren; Ernest F Terwilliger; Ramesh K Ganju
Journal:  Blood       Date:  2009-08-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.